Spectrum Pharmaceuticals Hit With Shareholder Class Action

Law360, New York (March 15, 2013, 3:32 PM EDT) -- Spectrum Pharmaceuticals Inc. was hit with a putative class action in Nevada federal court Thursday, accusing the biotechnology company of misleading investors about the sales potential of cancer treatment Fusilev, causing them to pay too much for the company's stock.

According to the plaintiffs, Spectrum shareholders John Perry and Judith Greenberg, Spectrum had made overly optimistic sales and revenue projections, despite knowing that Fusilev — one of the companies' two main products, alongside Zevalin, another cancer treatment — would soon face increased competition from a similar...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Perry et al v. Spectrum Pharmaceuticals, Inc. et al


Case Number

2:13-cv-00433

Court

Nevada

Nature of Suit

Securities/Commodities

Judge

Lloyd D. George

Date Filed

March 14, 2013

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.